All investors want to grow the value of their ASX stock portfolio, but safeguarding the wealth you've already built is just as important.
After all, the goal of wealth preservation is not just to grow your money, but protect it from risks which could dampen its value. And the way to do that is by investing it in a stable and reliable asset which only has more growth ahead.
Gold bars have traditionally been seen as the classic and steady wealth preservation tool. That's because gold tends to hold its value during volatile periods such as economic downturns or periods of high inflation.
But there is one stock which could look after your wealth much more effectively.
Image source: Getty Images
The ASX stock I'd pick for wealth
ResMed Inc (ASX: RMD) shares are highly regarded as a strong and stable stock which investors can buy and hold onto forever.
The company is a world leader in sleep and respiratory care. It develops, manufactures, and distributes medical devices and cloud-based software applications that diagnose, treat, and manage a range of respiratory disorders.
This includes conditions such as sleep apnea, chronic obstructive pulmonary disease (COPD), and neuromuscular disease.
ResMed also generates significant recurring revenue from consumables like masks and accessories, which patients need to replace regularly.
And because research and awareness around sleep-based disorders are growing by the month, the company should enjoy growth for years to come.
What do analysts think of the stock?
At the close of the ASX on Wednesday, ResMed shares were 0.02% lower at $40.94 a piece.
Over the past month the share price has fallen 6.53% but they're still up 12.94% higher for the year which shows robust growth.
Impressively, over the past 5 years the share price has risen 75.18%.
The ASX stock's share price trajectory throughout the past 12 months has been robust, but analysts expect even more upside going forward.
According to TradingView data on 29 analysts, 21 have a buy or strong buy rating on ResMed shares.
The average target price is $45.29 and the maximum is $50.86. That represents a potential upside of 10.6% to 24.2% over the next 12 months, at the time of writing.
Just last month Macquarie analysts confirmed their outperform rating on ResMed shares and raised its target price to $48.60.
Macquarie said it has raised its target price following earnings per share (EPS) revisions to reflect the company's updated operational forecasts and adjusted buyback assumptions.
